# Samsung Bioepis

Source: https://onco.cc/companies/samsung-bioepis/  
OnCo record `samsung-bioepis` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Samsung Bioepis develops biosimilars of trastuzumab, bevacizumab and other antibodies, made by its parent Samsung Biologics at Songdo.

## Summary

Samsung Bioepis was founded in 2012 as a joint venture between Samsung Biologics and Biogen and became wholly owned by Samsung Biologics in 2022. It develops biosimilars, among them trastuzumab (Ontruzant) and bevacizumab (Aybintio), which are manufactured at Samsung Biologics' Songdo plants and sold with partners in Europe and the United States.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Tags: manufacturing-wave
- HQ: Incheon
- Type: biotech
- Website: https://www.samsungbioepis.com

## Sources

- Official website: https://www.samsungbioepis.com

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- technologies: [Antibody manufacturing (CHO bioprocessing)](https://onco.cc/technologies/monoclonal-antibody-manufacturing/), [Biosimilar manufacturing and comparability](https://onco.cc/technologies/biosimilar-manufacturing/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)

---
JSON: https://onco.cc/api/v1/entities/samsung-bioepis.json